Lv0
0 积分 2025-02-19 加入
Obinutuzumab as Initial or Second-line Therapy in Patients With Primary Membranous Nephropathy
21天前
已完结
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
21天前
已完结
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
21天前
已完结
A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance
21天前
已完结
Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases
21天前
已完结
Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis
1个月前
已完结
Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells
1个月前
已完结
Adult minimal change nephropathy: experience of the collaborative study of glomerular disease
1个月前
已关闭
The Treatment of Minimal Change Disease in Adults
1个月前
已完结
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
皖公网安备34019202002308
